导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.23% | 3914/4773 |
| 近一周 | -2.56% | 4054/5465 |
| 近一月 | -2.81% | 1927/5421 |
| 近一季 | -2.46% | 1387/5231 |
| 近半年 | -4.27% | 2768/4920 |
| 近一年 | -15.28% | 3721/4394 |
| 近两年 | 30.52% | 2256/2954 |
| 近三年 | 10.89% | 1734/2253 |
| 成立以来 | -12.48% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.49% 4660/4961 |
8.96% 2513/5312 |
- - |
- - |
| 2025 | 3.99% 3078/4813 |
-6.65% 3380/3635 |
4.17% 840/4076 |
10.96% 3222/4524 |
-3.62% 3305/4813 |
| 2024 | 28.08% 168/3463 |
-4.80% 1767/2808 |
-8.22% 2192/3014 |
43.06% 24/3129 |
2.47% 941/3463 |
| 2023 | 3.87% 257/2656 |
3.92% 1090/2280 |
-2.84% 686/2385 |
7.43% 42/2515 |
-4.24% 928/2655 |
| 2022 | -24.85% 1266/2207 |
-17.99% 1286/1919 |
2.16% 1338/2016 |
-15.24% 1249/2113 |
5.82% 432/2208 |
| 2021 | -1.33% 794/1822 |
-13.96% 1163/1255 |
7.38% 685/1330 |
5.06% 298/1466 |
1.65% 851/1822 |
| 2020 | 24.59% 631/1250 |
-9.30% 670/1028 |
10.48% 766/1067 |
21.77% 39/1164 |
2.11% 1010/1184 |
| 2019 | 43.70% 188/1092 |
45.58% 26/754 |
-6.44% 507/804 |
-4.45% 771/850 |
10.41% 136/918 |
| 2018 | -23.24% 273/834 |
- - |
- - |
- - |
-1.58% 17/691 |
| 2017 | -6.64% 515/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.31% 357/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证全指证券公司指数(LOF)A VS. 长安沪深300非周期A(740101) |